Removing one mitochondrial protein protected mice from diet-induced obesity
Mice lacking the chaperone GRPEL2 stayed leaner on a high-fat diet and kept better insulin sensitivity — an early mechanistic finding, not a treatment, and so far only in mice.
A study published 22 August in the journal Mitochondrion found that mice engineered to lack a single mitochondrial protein, GRPEL2, gained less weight on a high-fat diet and with age, and kept better metabolic health, than normal mice [s1]. The finding, from a team led by Henna Tyynismaa at the University of Helsinki, points to a previously unrecognized role for mitochondrial protein-folding machinery in body weight regulation [s1].
This is a mouse study of basic mitochondrial biology, not a therapy or a human trial. It is an early mechanistic finding of the kind that sometimes — not usually — eventually leads somewhere clinically relevant.
What GRPEL2 does, and why the researchers looked at it
Mitochondria import proteins made elsewhere in the cell and fold them into working shape once inside. That folding cycle depends on a chaperone protein called mtHSP70, whose activity is regulated by a "nucleotide exchange factor" called GRPEL1. Vertebrates, including mice and humans, also carry a second, less-understood version called GRPEL2, long suspected to be a stress-response backup to GRPEL1 but never functionally tested in a living animal [s1].
The researchers created mice with GRPEL2 knocked out entirely to see what, if anything, changed.
What happened when GRPEL2 was removed
Two things stood out. First, unlike GRPEL1 — which is essential for mitochondrial function and whose loss triggers a cellular stress response — GRPEL2 turned out to be dispensable. Knockout mice survived normally and showed no signs of the proteotoxic stress that follows GRPEL1 loss [s1].
Second, and unexpectedly, the knockout mice were protected from weight gain. Both with age and on a high-fat diet, GRPEL2-deficient mice gained less weight than normal mice and maintained better insulin sensitivity — a marker of metabolic health that typically deteriorates with obesity [s1].
Looking for where in the body the effect was concentrated, the researchers profiled gene activity in liver, skeletal muscle, and white fat tissue. Liver and muscle showed minimal changes. White adipose tissue was where the difference showed up: fat tissue from the knockout mice lacked the structural remodeling that normally accompanies obesity in control mice [s1].
The researchers' interpretation
The team's proposed explanation is that GRPEL2 "fine-tunes metabolic setpoints without broadly perturbing mitochondrial protein import" — in other words, it appears to act on a fairly narrow, adjustable dial governing how fat tissue responds to excess calories, rather than on the core machinery mitochondria need to function [s1]. That distinction is what makes it interesting as a potential target: disrupting GRPEL1 or the core import pathway would be expected to cause broad cellular harm, but GRPEL2 loss did not.
The paper's own framing is exploratory: the authors describe the results as suggesting "strategies to mitigate obesity and insulin resistance through targeted modulation of mitochondrial proteostasis" [s1] — a hypothesis for future work, not a claim that GRPEL2 has been validated as a target.
What this doesn't show
This is one knockout-mouse study. It doesn't establish that GRPEL2 plays any comparable role in human metabolism, doesn't identify a drug or intervention that could modulate it, and doesn't show what happens over a longer time frame than the study covered or in the presence of other diseases. A large fraction of mouse metabolic findings — including other genes previously shown to protect against diet-induced obesity in mice — have not translated into human treatments. The gene activity profiling covered only three tissues, and the mechanism connecting GRPEL2 loss to adipose tissue's blunted response to a high-fat diet is not yet worked out at the molecular level.
What to watch next
Whether follow-up work identifies a way to pharmacologically inhibit GRPEL2 rather than genetically delete it, whether the effect holds in other mouse strains and diet models, and whether any human genetic or expression data connect GRPEL2 levels to body weight or metabolic disease.
This article describes preclinical mouse research. It is not medical advice and does not describe a treatment available to humans.
Sources
- Loss of mitochondrial co-chaperone GRPEL2 protects mice from age- and diet-induced obesity — Mitochondrion , August 22, 2026
More on
Is 'starvation mode' real? Your metabolism slows, but it can't stall fat loss
Losing weight lowers resting metabolism and keeps it low — Biggest Loser contestants ran hundreds of calories below baseline six years on. But that brake slows loss; it does not store fat.
Does your metabolism really slow down in your 30s and 40s?
A large study of energy use across the lifespan found it holds steady from age 20 to 60, once body size is accounted for. The midlife metabolic slump is mostly a myth; the decline comes later.
The first oral GLP-1 is approved. The needle was never the only barrier.
Orforglipron removes the injection from weight-loss medicine — a real change for people who refused one. Supply, cost, and coverage are the harder problems it does not solve.
Amino-acid patterns in childhood flagged diabetes risk a decade later
In 947 Chinese children followed for ten years, those with insulin resistance despite normal blood sugar had a 4.3-fold higher risk of later dysglycaemia, and six amino acids helped predict who would develop it.